Publication

Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT

de Hosson, L. D., van der Loo-van der Schaaf, A. M., Boellaard, R., van Snick, J. H., de Vries, E. G. E., Brouwers, A. H. & Walenkamp, A. M. E., Aug-2019, In : Clinical Nuclear Medicine. 44, 8, p. 612-619 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

de Hosson, L. D., van der Loo-van der Schaaf, A. M., Boellaard, R., van Snick, J. H., de Vries, E. G. E., Brouwers, A. H., & Walenkamp, A. M. E. (2019). Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT. Clinical Nuclear Medicine, 44(8), 612-619. https://doi.org/10.1097/RLU.0000000000002640

Author

de Hosson, Lotte D. ; van der Loo-van der Schaaf, Aline M. ; Boellaard, Ronald ; van Snick, Johannes H. ; de Vries, Elisabeth G. E. ; Brouwers, Adrienne H. ; Walenkamp, Annemiek M. E. / Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT. In: Clinical Nuclear Medicine. 2019 ; Vol. 44, No. 8. pp. 612-619.

Harvard

de Hosson, LD, van der Loo-van der Schaaf, AM, Boellaard, R, van Snick, JH, de Vries, EGE, Brouwers, AH & Walenkamp, AME 2019, 'Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT', Clinical Nuclear Medicine, vol. 44, no. 8, pp. 612-619. https://doi.org/10.1097/RLU.0000000000002640

Standard

Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT. / de Hosson, Lotte D.; van der Loo-van der Schaaf, Aline M.; Boellaard, Ronald; van Snick, Johannes H.; de Vries, Elisabeth G. E.; Brouwers, Adrienne H.; Walenkamp, Annemiek M. E.

In: Clinical Nuclear Medicine, Vol. 44, No. 8, 08.2019, p. 612-619.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

de Hosson LD, van der Loo-van der Schaaf AM, Boellaard R, van Snick JH, de Vries EGE, Brouwers AH et al. Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT. Clinical Nuclear Medicine. 2019 Aug;44(8):612-619. https://doi.org/10.1097/RLU.0000000000002640


BibTeX

@article{9e0a7de9dafc40f9b8503fa71ce86500,
title = "Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT",
abstract = "Purpose Neuroendocrine tumors (NETs) can produce neuroendocrine amines resulting in symptoms. Selecting the most active amine-producing tumor lesions for local treatment might be beneficial for patients with metastatic small intestinal NET. Tumor burden correlates with catecholamine pathway activity. We analyzed interlesional heterogeneity with F-18-DOPA PET scans in patients with small intestinal NET and investigated if lesions with substantially higher F-18-DOPA uptake could be identified. Methods In this retrospective, observational study, the F-18-DOPA uptake was calculated by dividing SUVpeak of the lesion by the SUVmean of the background organ. The magnitude of heterogeneity between lesions within a patient was calculated by dividing the lesion with the highest by the one with the lowest F-18-DOPA uptake. Lesions with a higher F-18-DOPA uptake than the upper inner or outer fence (>1.5 or 3 times the interquartile range above the third quartile) were defined as lesions with mild or extreme high F-18-DOPA uptake, respectively, and presence of these was determined in patients with 10 lesions or more. Results F-18-DOPA was detected over 680 lesions in 38 patients, of which 35 were serotonin producing. F-18-DOPA uptake varied with a median of 8-fold up to 44-fold between lesions within a patient. In 12 of 20 evaluable patients, lesions with mild high F-18-DOPA uptake were found, and in 5, lesions with extreme high F-18-DOPA uptake. Conclusions F-18-DOPA-PET showed considerable heterogeneity in F-18-DOPA uptake between tumor lesions and identified lesions within patients with mild or extreme high F-18-DOPA uptake.",
keywords = "F-18-DOPA PET scan, heterogeneity, neuroendocrine tumor, tracer uptake, LIVER-METASTASES, CARCINOID-TUMORS, GUIDELINES",
author = "{de Hosson}, {Lotte D.} and {van der Loo-van der Schaaf}, {Aline M.} and Ronald Boellaard and {van Snick}, {Johannes H.} and {de Vries}, {Elisabeth G. E.} and Brouwers, {Adrienne H.} and Walenkamp, {Annemiek M. E.}",
year = "2019",
month = aug,
doi = "10.1097/RLU.0000000000002640",
language = "English",
volume = "44",
pages = "612--619",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "8",

}

RIS

TY - JOUR

T1 - Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT

AU - de Hosson, Lotte D.

AU - van der Loo-van der Schaaf, Aline M.

AU - Boellaard, Ronald

AU - van Snick, Johannes H.

AU - de Vries, Elisabeth G. E.

AU - Brouwers, Adrienne H.

AU - Walenkamp, Annemiek M. E.

PY - 2019/8

Y1 - 2019/8

N2 - Purpose Neuroendocrine tumors (NETs) can produce neuroendocrine amines resulting in symptoms. Selecting the most active amine-producing tumor lesions for local treatment might be beneficial for patients with metastatic small intestinal NET. Tumor burden correlates with catecholamine pathway activity. We analyzed interlesional heterogeneity with F-18-DOPA PET scans in patients with small intestinal NET and investigated if lesions with substantially higher F-18-DOPA uptake could be identified. Methods In this retrospective, observational study, the F-18-DOPA uptake was calculated by dividing SUVpeak of the lesion by the SUVmean of the background organ. The magnitude of heterogeneity between lesions within a patient was calculated by dividing the lesion with the highest by the one with the lowest F-18-DOPA uptake. Lesions with a higher F-18-DOPA uptake than the upper inner or outer fence (>1.5 or 3 times the interquartile range above the third quartile) were defined as lesions with mild or extreme high F-18-DOPA uptake, respectively, and presence of these was determined in patients with 10 lesions or more. Results F-18-DOPA was detected over 680 lesions in 38 patients, of which 35 were serotonin producing. F-18-DOPA uptake varied with a median of 8-fold up to 44-fold between lesions within a patient. In 12 of 20 evaluable patients, lesions with mild high F-18-DOPA uptake were found, and in 5, lesions with extreme high F-18-DOPA uptake. Conclusions F-18-DOPA-PET showed considerable heterogeneity in F-18-DOPA uptake between tumor lesions and identified lesions within patients with mild or extreme high F-18-DOPA uptake.

AB - Purpose Neuroendocrine tumors (NETs) can produce neuroendocrine amines resulting in symptoms. Selecting the most active amine-producing tumor lesions for local treatment might be beneficial for patients with metastatic small intestinal NET. Tumor burden correlates with catecholamine pathway activity. We analyzed interlesional heterogeneity with F-18-DOPA PET scans in patients with small intestinal NET and investigated if lesions with substantially higher F-18-DOPA uptake could be identified. Methods In this retrospective, observational study, the F-18-DOPA uptake was calculated by dividing SUVpeak of the lesion by the SUVmean of the background organ. The magnitude of heterogeneity between lesions within a patient was calculated by dividing the lesion with the highest by the one with the lowest F-18-DOPA uptake. Lesions with a higher F-18-DOPA uptake than the upper inner or outer fence (>1.5 or 3 times the interquartile range above the third quartile) were defined as lesions with mild or extreme high F-18-DOPA uptake, respectively, and presence of these was determined in patients with 10 lesions or more. Results F-18-DOPA was detected over 680 lesions in 38 patients, of which 35 were serotonin producing. F-18-DOPA uptake varied with a median of 8-fold up to 44-fold between lesions within a patient. In 12 of 20 evaluable patients, lesions with mild high F-18-DOPA uptake were found, and in 5, lesions with extreme high F-18-DOPA uptake. Conclusions F-18-DOPA-PET showed considerable heterogeneity in F-18-DOPA uptake between tumor lesions and identified lesions within patients with mild or extreme high F-18-DOPA uptake.

KW - F-18-DOPA PET scan

KW - heterogeneity

KW - neuroendocrine tumor

KW - tracer uptake

KW - LIVER-METASTASES

KW - CARCINOID-TUMORS

KW - GUIDELINES

U2 - 10.1097/RLU.0000000000002640

DO - 10.1097/RLU.0000000000002640

M3 - Article

VL - 44

SP - 612

EP - 619

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 8

ER -

ID: 95558181